Real world experience of approved chimeric antigen receptor T-cell therapies outside of clinical trials
Author:
Publisher
Elsevier BV
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference78 articles.
1. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020
2. Diffuse large B-cell lymphoma;Li;Pathology,2018
3. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med,1995
4. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study;Crump;Blood,2017
5. Acute lymphoblastic leukaemia;Malard;Lancet,2020
Cited by 27 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. CAR T-lymphocytes in the treatment of non-Hodkgin's lymphoma: current perspectives;Onkologie;2024-05-03
2. Blood–brain barrier breakdown, central nervous system cell damage, and infiltrated T cells as major adverse effects in CAR-T-related deaths: a literature review;Frontiers in Medicine;2024-01-08
3. Effectiveness and safety of CD22 and CD19 dual‐targeting chimeric antigen receptor T‐cell therapy in patients with relapsed or refractory B‐cell malignancies: A meta‐analysis;Cancer Medicine;2023-09
4. Challenges and new technologies in adoptive cell therapy;Journal of Hematology & Oncology;2023-08-18
5. An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA;HemaSphere;2023-04-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3